EUVIMEDEUVIMED entdecken
Crossref

Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis

Yunlu Jia, Yongxia Chen, Ming Chen, Mengye He, Suzhen Xu, Han Li, Xuanyi Lin, Linbo Wang, Jichun Zhou, Peng Shen, Xiao Luo, Xiaochen Zhang und 1 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Yunlu Jia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Tumor Suppressor Protein p53, Forkhead Box Protein M1, E2F1 Transcription Factor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Health Commission of Zhejiang Province, Zhejiang Administration Bureau of Traditional Chinese Medicine, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, lacking effective targeted therapies and presenting with a poor prognosis. In this study, we utilized the epigenomic landscape, TCGA database, and clinical samples to uncover the pivotal role of HJURP in TNBC. Our investigation revealed a strong correlation between elevated HJURP expression and unfavorable prognosis, metastatic progression, and late-stage of breast cancer. RNA-seq analysis indicated that HJURP silencing suppressed transcriptional signatures associated with malignant phenotypes of TNBC, thereby inhibiting cell proliferation, migration, invasion, epithelial-to-mesenchymal transition (EMT), and promoting apoptosis. Knockdown of HJURP impaired the growth of MDA-MB231-engrafted tumors, reducing KI67 and HJURP expression in the shHJURP group. Publicly available datasets showed differential expression of HJURP in TNBC cells harboring mutant p53 (mutp53) compared to those with wild-type p53 (wtp53), highlighting a potential mechanism underlying TNBC's aggressiveness. Mechanistically, we established that loss or mutation of wtp53 enhances HJURP expression, whereas wtp53 accumulation restrains HJURP transcription. We elucidated a regulatory axis where wtp53 positively modulates the transcription factors FOXM1 and E2F1, which form a complex with H3K27ac to bind preferentially to the HJURP enhancer, driving its transcription. CRISPR interference targeting the enhancer region resulted in diminished HJURP expression and phenotypes reminiscent of HJURP knockdown, accompanied by reduced binding of E2F1, FOXM1, and H3K27ac to the enhancer. In a translational perspective, we found marked decreases in survival of breast cancer patients expressing high HJURP levels carrying wtp53. Collectively, our findings identify enhancer-driven HJURP as a pivotal molecular bypass that suppresses the tumor-suppressive and pro-apoptotic effects of wtp53. Targeting HJURP presents a compelling therapeutic strategy to inhibit tumor proliferation, metastasis, and invasiveness specifically p53-mutant TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsTumor Suppressor Protein p53Forkhead Box Protein M1E2F1 Transcription FactorHumansFemaleGene Expression Regulation, NeoplasticCell ProliferationAnimalsCell Line, TumorEnhancer Elements, GeneticCell MovementEpithelial-Mesenchymal TransitionApoptosisSignal TransductionMiceMDA-MB-231 CellsNeoplasm InvasivenessBromodomain Containing ProteinsNerve Tissue ProteinsTranscription FactorsAntigens, Nuclear

Stichwörter der Autor:innen

E2F1EnhancersFOXM1HJURPTNBCp53

Substanzen

Tumor Suppressor Protein p53Forkhead Box Protein M1E2F1 Transcription FactorFOXM1 protein, humanTP53 protein, humanE2F1 protein, humanfetal Alzheimer antigenBromodomain Containing ProteinsNerve Tissue ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310020, China.
  • The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China.
  • Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Electronic address: luoxiao1990@zju.edu.cn.
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: zhangxiaochen@zju.edu.cn.
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Electronic address: software233@zju.edu.cn.

Förderung

  • Health Commission of Zhejiang Province
  • Zhejiang Administration Bureau of Traditional Chinese Medicine
  • Natural Science Foundation of Zhejiang Province
  • Zhejiang Provincial Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Jia, Y., Chen, Y., Chen, M., He, M., Xu, S., Li, H., Lin, X., Wang, L., Zhou, J., Shen, P., Luo, X., Zhang, X., & Ruan, J. (2025). Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217423

Vancouver

Jia Y, Chen Y, Chen M, He M, Xu S, Li H, et al. Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217423

BibTeX
@article{Jia2025,
  author = {Jia, Yunlu and Chen, Yongxia and Chen, Ming and He, Mengye and Xu, Suzhen and Li, Han and Lin, Xuanyi and Wang, Linbo and Zhou, Jichun and Shen, Peng and Luo, Xiao and Zhang, Xiaochen and Ruan, Jian},
  title = {Oncogenic HJURP enhancer promotes the aggressive behavior of triple-negative breast cancer in association with p53/E2F1/FOXM1-axis},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217423}
}
Kostenlos starten →